# Therapy Monitor Multiple Myeloma Germany

**First published:** 01/02/2024

Last updated: 17/10/2024







# Administrative details

# Administrative details

#### **PURI**

https://redirect.ema.europa.eu/resource/1111168

#### **Data source ID**

1111168

#### Data source acronym

TM MM DE

#### **Data holder**

TriNetX Oncology GmbH

#### **Data source type**

Other

#### Data source type, other

**Curated Chart Review Database** 

#### Main financial support

Funding from industry or contract research

### **Care setting**

Other

#### **Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

#### **Data source website**

https://trinetx.com/products/consulting-services/tnxogmbh/

# Contact details

# Stefan Schilling



stefan.schilling@trinetx.com

# Data source regions and languages

#### **Data source countries**

Germany

#### **Data source languages**

German

### Data source establishment

#### **Data source established**

01/01/2016

### **Data source time span**

First collection: 01/01/2016

The date when data started to be collected or extracted.

## **Publications**

# Data source publications

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma in Europe from 2016 to 2018:Analysis of a Multi-National Survey

Treatment Patterns in Patients with Refractory/Relapsed Multiple Myeloma in Germany Between 2016 and 2018

Baseline characteristics and survival outcomes of patients with tri-exposed multiple myeloma in a German registry

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD-38 from a German registry

Diagnosis and treatment of multiple myeloma in Germany – Analysis of a nationwide, multi-institutional survey

## Data elements collected

The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

Yes

#### Disease details (other)

Multiple myeloma, including all diagnostic and clinical variables acording to current guidelines for each time point of treatment decision after disease progression, retrospectively to the initial diagnosis. Disease and treatment characteristics include relevant biomarkers, labs, limited information on care-relevant comorbidities, detailed descriptions on disease-specific interventions and/or therapy measures (systemic therapy, stem cell transplant and CAR-T cell therapy), details of progression controls performed, best response, treatment pauses/interruption/modification and reason change in treatment plan.

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

### Pregnancy and/or neonates

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

No

### Hospital admission and/or discharge

No

#### **ICU** admission

Is information on intensive care unit admission available?  No		
Cause of death		
Not Captured		
Prescriptions of medicines		
Captured		
Dispensing of medicines		
Not Captured		
Advanced therapy medicinal products (ATMP)		
Is information on advanced therapy medicinal products included? A medicinal product for human		
use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue		
engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)]		
No		
Contraception		
Is information on the use of any type of contraception (oral, injectable, devices etc.) available?		
No		
Indication for use		
Does the data source capture information on the therapeutic indication for the use of medicinal products?		
Captured		

# Indication vocabulary

ICD-10

### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

#### **Administration of vaccines**

No

#### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

#### **Procedures vocabulary**

Not coded (Free text)

#### **Healthcare** provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

#### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

#### **Genetic data**

Are data related to genotyping, genome sequencing available?

Captured

### **Genetic data vocabulary**

Other

#### Genetic data vocabulary, other

Standard vocabulary not used

#### Biomarker data

Does the data source capture biomarker information? The term "biomarker" refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

### **Biomarker data vocabulary**

Other

#### Biomarker vocabulary, other

Standard vocabulary not used

#### **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

No

### **Patient-generated data**

Is patient-generated information (e.g., from wearable devices) available?

No

#### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

### **Unique identifier for persons**

Diagnostic codes	
Captured	
Diagnosis / medical event vocabulary	•
Not coded (Free text)	
Medicinal product information	
Captured	
Medicinal product information collect	ted
Active ingredient(s)	
Dose	
Dosage regime	
Route of administration	
Brand name	
Medicinal product vocabulary	
Not coded (Free text)	
Quality of life measurements	
Not Captured	
Lifestyle factors	
Captured	
Lifestyle factors	
Other	

Are patients uniquely identified in the data source?

#### Sociodemographic information

Captured

### Sociodemographic information collected

Age

Gender

Education level

Health area

# Quantitative descriptors

# Population Qualitative Data

#### Population age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

# Estimated percentage of the population covered by the data source in the catchment area

12-13% of the treated prevalence in Germany based on internal MM prevalence projections from 2018 coherent with secondary official sources (RKI) and accepted by the G-BA and for AMNOG submissions.

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

Captured population has complete data reporting.

# **Population**

### **Population size**

8412

### **Active population size**

3762

# Population by age group

Age group	Population size	Active population size
Adults (18 to < 46 years)	73	41
Adults (46 to < 65 years)	1569	815
Elderly (≥ 65 years)	6770	2906
Adults (65 to < 75 years)	3722	1488
Adults (75 to < 85 years)	2689	1255
Adults (85 years and over)	359	163

# Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

6.50

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

3.00

# Data flows and management

# Access and validation

#### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

### Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

Yes

#### **Description of data collection**

Participating centers enter data from patient records to an online eCRF created by TriNetX Oncology GmbH in the current version of secuTrial™ (iAS GmbH, Berlin, Germany). Participant selection is driven by the distribution of the number of MM patients in the relevant health care sectors (university hospitals, non-university hospitals, office-based practice) obtained from in-house health care structure analyses. The documenting physician transfers the existing data from the patient file to the online documentation form retrospectively from the

current point in time (end of the observation period) to the initial diagnosis of the disease.

# Event triggering registration

#### Event triggering registration of a person in the data source

Start of treatment

#### Event triggering de-registration of a person in the data source

Death

Loss to follow up

Other

#### Event triggering de-registration of a person in the data source, other

Patient's who have been de-registered remain in the database for retrospectice and longitudinal analyses.

#### Event triggering creation of a record in the data source

New patient meeting the inclusion criteria is reported via eCRF by the participating physician

# Data source linkage

#### Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

# Data management specifications that apply for the data source

#### **Data source refresh**

Quarterly

#### Informed consent for use of data for research

Not Required

#### Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

Yes

#### **Data source preservation**

Are records preserved in the data source indefinitely?

Yes

### **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

No

#### Data source last refresh

31/12/2022

# Common Data Model (CDM) mapping

### **CDM** mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

### **CDM Mappings**

О	DMOP	
C	DM website	
h	ttns://www.ohdsi.org/Data-standardization/	

### **Data source ETL CDM version**

5.4

# **Data source ETL frequency**

6,00 months

**CDM** name

### **Data source ETL status**

Completed